Nusinersen sodium
Spinraza (nusinersen sodium) is an oligonucleotide pharmaceutical. Nusinersen sodium was first approved as Spinraza on 2017-05-30. It has been approved in Europe to treat spinal muscular atrophy. Spinraza's patents are valid until 2035-09-11 (FDA).
Trade Name | Spinraza |
---|---|
Common Name | Nusinersen sodium |
Indication | spinal muscular atrophy |
Drug Class | Antisense oligonucleotides |